Cetera Investment Advisers
LGND icon

Cetera Investment Advisers’s Ligand Pharmaceuticals LGND Stock Holding History

Cetera Investment Advisers’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$850K Buy
4,259
+924
+28% +$183K ﹤0.01% 3044
2025
Q4 		$631K Buy
3,335
+1,759
+112% +$338K ﹤0.01% 3238
2025
Q3 		$279K Buy
+1,576
New +$234K ﹤0.01% 3888

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Cetera Investment Advisers's LGND Position: Q1 2026 in Review

Cetera Investment Advisers increased its Ligand Pharmaceuticals (LGND) stake by 28% in Q1 2026, buying an estimated $183K and bringing the position to 4,259 shares worth $850K. The position accounts for ﹤0.01% of the portfolio, ranked #3044.

Cetera Investment Advisers first reported a position in LGND in Q3 2025 and has held it in 3 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Cetera Investment Advisers held 4,259 shares of Ligand Pharmaceuticals worth $850K as of Q1 2026.
  • Cetera Investment Advisers bought 924 Ligand Pharmaceuticals shares in Q1 2026, an estimated $183K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #3044 holding.
  • Cetera Investment Advisers first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.